Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 97
- 试验地点
- 2
- 主要终点
- CA125 ELISPOT assay response for cytotoxic T cell antigen specific immunity induction to end of first-line chemotherapy
研究概览
简要总结
This is a Phase 2 randomized study with two treatment arms to compare the effectiveness of oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy (carboplatin and paclitaxel alone) in female patients with advanced ovarian cancer.
详细描述
Oregovomab is an investigational drug previously used in clinical trials as an immunotherapeutic treatment of ovarian cancer patients whose tumor cells express the tumor associated antigen, CA125. The active component of oregovomab is the activated murine monoclonal antibody B43.13, an immunoglobulin G1k (IgG1k) subclass immunoglobulin that binds with high affinity (1.16E10/M) to CA125.
CA125 is a surface glycoprotein antigen that is expressed on more than 80% of all non-mucinous epithelial ovarian carcinomas where it occurs at elevated levels in the serum of patients with ovarian cancer. Little is known about its biological function. CA125 is associated with a large molecular weight mucin-like glycoprotein complex of 200-250 kilodaltons (kDa) and its genetic structure has recently been elucidated. There is good evidence to suggest that CA125 is a relevant target antigen for antigen-mediated immunotherapy of ovarian cancer.
The study will compare the effectiveness of oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy (carboplatin and paclitaxel alone) in female patients with advanced ovarian cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •have newly diagnosed epithelial adenocarcinoma of ovarian, tubal or peritoneal origin and French Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) Stage III/IV disease.
- •have preoperative CA125 levels > 50 U/mL
- •have optimal cytoreduction (RT<1)
- •be anticipated to have first-line chemotherapy infusion within 6 weeks after surgery
- •be available to complete the protocol for the duration of the study
- •have adequate Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1,500/µL, equivalent to Common Terminology Criteria (CTCAE v3.0) grade
- •Platelets greater than or equal to 100,000/µL; hemoglobin greater than or equal to 8.0 g/dL
- •have adequate Renal function: creatinine less than or equal to 1.5 x institutional upper limit normal (ULN), CTCAE v3.0 grade 1
- •have adequate Hepatic function: bilirubin less than or equal to 1.5 x ULN (CTCAE v3.0 grade 1). SGOT and alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)
- •able to sign informed consent and provide authorization permitting release of personal health information
- •have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
排除标准
- •have an active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis)
- •have a known allergy to murine proteins or have had a documented anaphylactic reaction to any drug, or cannot tolerate cyclophosphamide
- •are being chronically treated with immunosuppressive drugs such as cyclosporin, adrenocorticotropic hormone (ACTH), or systemic corticosteroids.
- •have a recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia
- •have an acquired, hereditary, or congenital immunodeficiency
- •have uncontrolled diseases other than cancer
- •have contraindications to the use of pressor agents
- •have undergone more than one surgical debulking
- •have hepatic dysfunction, eg, bilirubin more than 1.5 times higher than normal levels, lactate dehydrogenase (LDH), serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) doubled compared to normal or albumin <3.5 g/dL
- •have severe renal insufficiency with serum creatinine >1.6 mg/dL
- •have concomitant diseases or treatments that may confound the results of the study, which may preclude the completion of the protocol or may mask adverse reactions
- •are to be tested with other medications during treatment
- •are unable to read or understand or unable to sign the necessary written consent before starting treatment
研究组 & 干预措施
carboplatin & paclitaxel & oregovomab
first-line chemotherapy for ovarian cancer plus oregovomab
干预措施: Carboplatin (Drug)
carboplatin & paclitaxel
first-line chemotherapy for ovarian cancer
干预措施: Carboplatin (Drug)
carboplatin & paclitaxel
first-line chemotherapy for ovarian cancer
干预措施: Paclitaxel (Drug)
carboplatin & paclitaxel & oregovomab
first-line chemotherapy for ovarian cancer plus oregovomab
干预措施: Paclitaxel (Drug)
carboplatin & paclitaxel & oregovomab
first-line chemotherapy for ovarian cancer plus oregovomab
干预措施: oregovomab (Biological)
结局指标
主要结局
CA125 ELISPOT assay response for cytotoxic T cell antigen specific immunity induction to end of first-line chemotherapy
时间窗: At Baseline (up to 4 weeks before Cycle 1), at Cycle 5 (approximately 12 weeks after Cycle 1) and termination (approximately 25 weeks after Cycle 1)
Change from baseline CA125 ELISPOT assay after stimulation with oregovomab (MAb-B43.13 against CA125) measured at approximately 12 weeks and 25 weeks after the start of first-line chemotherapy
次要结局
- Immune parameters: HAMA (human anti-mouse antibody) titers and DTH (delayed type hypersensitivity)(Up to three years after treatment in the study)
- Clinical response(Up to three years after treatment in the study)
- Overall Survival(Up to three years after treatment in the study)
- Time to clinical relapse(Up to three years after treatment in the study)